Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736367 · ClinicalTrials.gov registry record · NA
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
A NA study of Breast Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT05736367: Recruiting NA study of Breast Cancer, sponsored by Rutgers, The State University of New Jersey.
NCT05736367 is a NA study of Breast Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 16 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736367, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Primary Outcome
To analyze and describe the metabolism of these tumors in vivo uniformly-labeled (U-13C)-glucose-labeled biopsy of tumor and benign adjacent tissue. The participants will receive glucose infusion and their tumor specimens analyzed. Blood collection will allow for in depth evaluation of glycolysis metabolism. Compounds can range from low molecular mass analytes with m/z values \< 1000 Da, to very high molecular mass proteins with m/z values \> 100,000 Da U-13C-Glucose (study drug)
Conditions Studied
Interventions
- DRUG U-13C-glucose
Study Locations (2)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT05736367 shows while recruiting
NCT05736367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which U-13C-glucose is the first listed.
NCT05736367 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05736367 about?
NCT05736367 is a clinical study titled "Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer". To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
What is the current status of trial NCT05736367?
This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2024-11-15. Estimated completion is 2028-06-30.
What conditions does trial NCT05736367 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05736367?
The interventions under investigation include: U-13C-glucose (DRUG).
Who is sponsoring clinical trial NCT05736367?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736367 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05736367's enrollment target sits among peer trials
16 1135th of 1224 higher than 82 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI